An Overview of Epigenetic Changes in the Parkinson's Disease Brain

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 19

PMID 38892355

Authors

Anthony Klokkaris

Anna Migdalska-Richards

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease is a progressive neurodegenerative disorder, predominantly of the motor system. Although some genetic components and cellular mechanisms of Parkinson's have been identified, much is still unknown. In recent years, emerging evidence has indicated that non-DNA-sequence variation (in particular epigenetic mechanisms) is likely to play a crucial role in the development and progression of the disease. Here, we present an up-to-date overview of epigenetic processes including DNA methylation, DNA hydroxymethylation, histone modifications and non-coding RNAs implicated in the brain of those with Parkinson's disease. We will also discuss the limitations of current epigenetic research in Parkinson's disease, the advantages of simultaneously studying genetics and epigenetics, and putative novel epigenetic therapies.

Citing Articles

Synergistic Neuroprotection Through Epigenetic Modulation by Combined Curcumin-Enriched Turmeric Extract and L-Ascorbic Acid in Oxidative Stress-Induced SH-SY5Y Cell Damage.

Khongrum J, Mairuae N, Thanchomnang T, Zhang M, Bai G, Palachai N Foods. 2025; 14(5).

PMID: 40077595 PMC: 11898916. DOI: 10.3390/foods14050892.

Epigenetic Mechanisms Underlying Sex Differences in Neurodegenerative Diseases.

Stoccoro A Biology (Basel). 2025; 14(1).

PMID: 39857328 PMC: 11761232. DOI: 10.3390/biology14010098.

Epigenetic Modifiers: Exploring the Roles of Histone Methyltransferases and Demethylases in Cancer and Neurodegeneration.

Reed L, Abraham J, Patel S, Dhar S Biology (Basel). 2025; 13(12.

PMID: 39765675 PMC: 11673268. DOI: 10.3390/biology13121008.

References

Stoger R, Scaife P, Shephard F, Chakrabarti L . Elevated 5hmC levels characterize DNA of the cerebellum in Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:6. PMC: 5460211. DOI: 10.1038/s41531-017-0007-3. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Zhu Z, Zhang F, Hu H, Bakshi A, Robinson M, Powell J . Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016; 48(5):481-7. DOI: 10.1038/ng.3538. View

Fahn S . Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci. 2003; 991:1-14. DOI: 10.1111/j.1749-6632.2003.tb07458.x. View

Topper M, Vaz M, Marrone K, Brahmer J, Baylin S . The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol. 2019; 17(2):75-90. PMC: 7254932. DOI: 10.1038/s41571-019-0266-5. View

Kim W, Lee Y, McKenna N, Yi M, Simunovic F, Wang Y . miR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling. Neurobiol Aging. 2014; 35(7):1712-21. PMC: 3991567. DOI: 10.1016/j.neurobiolaging.2014.01.021. View

Kaut O, Schmitt I, Stahl F, Frohlich H, Hoffmann P, Gonzalez F . Epigenome-Wide Analysis of DNA Methylation in Parkinson's Disease Cortex. Life (Basel). 2022; 12(4). PMC: 9025601. DOI: 10.3390/life12040502. View

Sharma S, Taliyan R, Singh S . Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity. Behav Brain Res. 2015; 291:306-314. DOI: 10.1016/j.bbr.2015.05.052. View

Min S, Xu Q, Qin L, Li Y, Li Z, Chen C . Altered hydroxymethylome in the substantia nigra of Parkinson's disease. Hum Mol Genet. 2022; 31(20):3494-3503. PMC: 9558850. DOI: 10.1093/hmg/ddac122. View

10.

Hu Y, Zhang Y, Wang H, Ren R, Cui H, Huang W . miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson's disease. Cell Death Dis. 2019; 10(8):589. PMC: 6683159. DOI: 10.1038/s41419-019-1809-5. View

11.

Meka S, Bojja S, Kumar G, Birangal S, Rao C . Novel HDAC inhibitors provide neuroprotection in MPTP-induced Parkinson's disease model of rats. Eur J Pharmacol. 2023; 959:176067. DOI: 10.1016/j.ejphar.2023.176067. View

12.

Masliah E, Dumaop W, Galasko D, Desplats P . Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics. 2013; 8(10):1030-8. PMC: 3891683. DOI: 10.4161/epi.25865. View

13.

Liu J, Wang F, Liu S, Du J, Hu X, Xiong J . Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. 2017; 381:176-181. DOI: 10.1016/j.jns.2017.08.3235. View

14.

Schlaudraff F, Grundemann J, Fauler M, Dragicevic E, Hardy J, Liss B . Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol Aging. 2014; 35(10):2302-15. PMC: 4099518. DOI: 10.1016/j.neurobiolaging.2014.03.016. View

15.

Scheper M, Iyer A, Anink J, Mesarosova L, Mills J, Aronica E . Dysregulation of miR-543 in Parkinson's disease: Impact on the neuroprotective gene SIRT1. Neuropathol Appl Neurobiol. 2022; 49(1):e12864. PMC: 10100056. DOI: 10.1111/nan.12864. View

16.

Lee A, Kim C, Park S, Joo J, Choi B, Yang D . Characterization of altered molecular mechanisms in Parkinson's disease through cell type-resolved multiomics analyses. Sci Adv. 2023; 9(15):eabo2467. PMC: 10104466. DOI: 10.1126/sciadv.abo2467. View

17.

Zhou J, Zhao Y, Li Z, Zhu M, Wang Z, Li Y . miR-103a-3p regulates mitophagy in Parkinson's disease through Parkin/Ambra1 signaling. Pharmacol Res. 2020; 160:105197. DOI: 10.1016/j.phrs.2020.105197. View

18.

Gong X, Huang M, Chen L . Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson's Disease. eNeuro. 2022; 9(1). PMC: 8805200. DOI: 10.1523/ENEURO.0393-21.2021. View

19.

Marshall L, Killinger B, Ensink E, Li P, Li K, Cui W . Epigenomic analysis of Parkinson's disease neurons identifies Tet2 loss as neuroprotective. Nat Neurosci. 2020; 23(10):1203-1214. DOI: 10.1038/s41593-020-0690-y. View

20.

Smith A, Richards D, Lunnon K, Schapira A, Migdalska-Richards A . DNA Methylation of α-Synuclein Intron 1 Is Significantly Decreased in the Frontal Cortex of Parkinson's Individuals with Mutations. Int J Mol Sci. 2023; 24(3). PMC: 9917152. DOI: 10.3390/ijms24032687. View